Today’s AI Top Pick: SMMT

9/30/2026 · Highly Shorted Deep Rotation RSI & Conf screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

The desk streams live daily· see the schedule →

Measured daily model accuracy · SMMT84%464 resolved forecasts · 45d window · verify →

Today's pick · Highly Shorted Deep Rotation RSI & ConfSMMTBUY NOW8.3 / 109/30/2026

Summit Therapeutics (SMMT) is the best risk/reward entry right now because it uniquely combines a genuine, high-conviction fundamental catalyst with clean multi-timeframe confirmation and a non-stretched entry. The dominant catalyst is the AstraZeneca $2 billion investment/stake, reported 2026-09-29, which drove a 17% single-day jump and represents institutional validation of the pipeline — not speculative hype. On the tape, SMMT shows near-term bullish confirmation (near_term_bullish = 1, bullish_prob = 0.4) with the 1h, 1d, and 1wk timeframes all aligned constructively: the 1d forecast runs fc_mid_pct 5.05 / fc_long_pct 4.7 and the 1wk fc_long_pct -19.83 is the mildest drawdown of any candidate with a bullish setup, meaning the stock is not overextended. Critically, position_in_21bar_range_pct sits at 51-51% on the 1h and 1d — dead center of the range, not at the top — so we are buying mid-range rather than chasing a parabolic bar. The 4h is the only laggard (fc_mid_pct -3.32), consistent with a stock that just ran 17% and needs to digest gains, which is exactly why the entry is attractive rather than a landmine. Fundamentally, SMMT is a cash-rich, low-debt biotech (debtEq = 0.03, marketCap $13.08B) with epsNextY of 2.65 and a 81.7% analyst target upside, so the downside is funded and the upside is analyst-endorsed. Unlike KULR (operMargin -258%, profitMargin -607%) or SERV (operMargin -2447%), SMMT's negative earnings are biotech-standard pre-revenue, not a deteriorating operating business. Unlike WING, which carries a -54.46% YTD drawdown and a crowded short float, SMMT's catalyst is forward-looking and idiosyncratic. The entry is compelling TODAY because the AZ catalyst is fresh (3 days old) and the stock is consolidating mid-range rather than extended — waiting risks a follow-through gap up on renewed AZ-driven interest, while the 4h digest provides a natural, low-risk accumulation window. The key reason SMMT edges PSIX (the highest raw score) is entry quality and catalyst durability. PSIX is beautifully aligned on 4h/1d/1wk but is sitting at position_in_21bar_range_pct of 99-100% — essentially at the top of its 21-bar range on multiple timeframes — which is a chase signal, not an accumulation zone. SMMT's mid-range entry with a fresh institutional catalyst offers a superior risk/reward asymmetry at this exact moment.

Entry zone

Accumulate on the 4h digest between $15.80 and $16.35 (current $16.35); add on any pullback toward $15.50 where the 1d fc support holds

Stop loss

Close below $14.90 (below the -11.23% 1d drawdown band and the 21-bar low)

First target

$18.50 (near-term bounce off mid-range on continued AZ bid)

Longer target

$21.00-$22.00 (swing target toward the analyst-implied upside, ~81.7% from prior base)

Risks

4h timeframe is the only laggard (fc_mid_pct -3.32, fc_long_pct -19.83), indicating near-term exhaustion after the 17% jump — a multi-day consolidation risk
Biotech binary risk: SMMT is pre-revenue with negative margins; any pipeline setback on the AZ asset could trigger a sharp drawdown
Post-catalyst fade risk: the 17% single-day move may have front-ran the AZ thesis, leaving limited near-term upside if buyers exit
Concentration on a single partner (AstraZeneca) — loss of that relationship or deal renegotiation would be materially negative
Low near-term bullish_prob (0.4) and near_term_bullish = 1 are model signals, not guarantees, and could reverse on broad biotech weakness

Honorable mentions

PSIXHighest raw score (14.25) with strong 4h/1d/1wk alignment and a 48.2% target upside, but sits at position_in_21bar_range_pct 99-100% — at the top of the range on multiple timeframes, making it a chase rather than an accumulation. Best as a BUY_PULLBACK: wait for a pullback to mid-range ($44-$45) before entering.

SMMTAlready the winner; if excluded, STAA (Staar Surgical) is the next best — fresh Stifel upgrade citing China growth, 8% single-day pop, and clean 1h/1d/1wk alignment with near_term_bullish = 0.8, though the 337x PE warrants caution.

WINGStrong fundamentals (25.79 PE, 82.62% gross margin, 83.6% target upside) and 1h/4h/1d/1wk coverage, but the -54.46% YTD drawdown and crowded short float (18.33%) make it a higher-volatility BUY_PULLBACK rather than a top pick.

Full ranking (27)

#	Symbol	Verdict	Score	Read
1	SMMT	BUY NOW	8.3	Fresh $2B AstraZeneca catalyst with mid-range entry and clean multi-timeframe alignment — best risk/reward today.
2	PSIX	BUY PULLBACK	8.0	Strong alignment but sitting at the top of its 21-bar range (99-100%) — wait for a pullback to enter.
3	STAA	BUY PULLBACK	7.5	Stifel upgrade + China growth catalyst, but 337x PE and -20% 4h drawdown argue for a pullback entry.
4	WING	BUY PULLBACK	7.2	High-quality business and full-timeframe coverage, but -54% YTD drop and crowded short float favor patience.
5	MNRO	BUY PULLBACK	6.8	31% short float squeeze candidate with 1d/1wk alignment, but 'Hold' consensus caps near-term upside.
6	SERV	WAIT	6.5	40% short float and $240M cash support a squeeze narrative, but -2447% operating margins are a landmine.
7	KULR	WAIT	6.2	Cheap cash-runway story but -258% operating margin and -39% 4h drawdown signal a fragile setup.
8	TSSI	WAIT	5.9	Margin improvement narrative intact but 1h/1wk forecasts negative — needs clearer confirmation.
9	CRMD	BUY PULLBACK	5.6	Oppenheimer Outperform + $15 target is a clean catalyst, but -10.77% 4h drawdown argues for a pullback entry.
10	BTBT	WAIT	5.3	Crypto-correlated with 18% short float; 1d forecast positive but sector beta adds volatility risk.
11	EBS	BUY PULLBACK	5.0	HC Wainwright Buy + $10 target, but -18% 4h drawdown and Naloxone margin concern favor a pullback.
12	GRRR	WAIT	4.7	AI GPU catalysts are strong but -33% 4h drawdown and negative margins need stabilization.
13	DUOT	WAIT	4.4	Insider buying + Buy rating are positive, but near_term_bullish = 0 caps conviction.
14	LQDA	WAIT	4.1	Buy-rating momentum but -14% 4h and -35% 1d forecasts show near-term weakness.
15	GRND	WAIT	3.8	Downgraded to Hold with valuation concerns; 1d forecast negative despite strong fundamentals.
16	ARQQ	WAIT	3.5	Quantum-safe narrative intact but -19% 4h/1d forecasts and 385x PS flag stretched valuation.
17	AMKR	WAIT	3.2	Semiconductor recovery story but -33% 4h drawdown and negative 1d/1wk forecasts need reversal confirmation.
18	OMER	WAIT	2.9	Overweight upgrade + $22 target is positive, but -48% 4h and -57% 1d forecasts show weakness.
19	UPXI	WAIT	2.6	1h forecast strong (164%) but 1d/1wk negative — inconsistent multi-timeframe signal.
20	RXRX	WAIT	2.3	AI-drug catalysts intact but -991% operating margin and negative 1d forecast flag fragility.
21	CEPT	WAIT	2.0	48.8% short float is a squeeze candidate but only 1d data available and -12% drawdown limits conviction.
22	XPOF	BUY PULLBACK	1.7	UBS lowered target on weaker sales — guidance concern, but 1d/1wk alignment supports a pullback entry.
23	SEI	WAIT	1.4	$1.25B notes add leverage risk and -14% 4h drawdown outweighs the earnings outperform.
24	GEMI	WAIT	1.1	Crypto-beta with -293% operating margin and negative forecasts — speculative, needs clarity.
25	TGTX	WAIT	0.8	$1B run-rate catalyst is strong but -40% 1d forecast and 56x PE need stabilization.
26	ARQT	WAIT	0.5	Simone Biles campaign is positive but -17% 4h and -25% 1d forecasts show near-term weakness.
27	PRGO	WAIT	0.2	13.8% post-earnings pop is encouraging but -42% 1d forecast and negative margins limit appeal.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord